Zacks: Brokerages Anticipate Genomic Health, Inc. (GHDX) Will Post Quarterly Sales of $86.09 Million
Analysts expect that Genomic Health, Inc. (NASDAQ:GHDX) will post $86.09 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Genomic Health’s earnings, with the lowest sales estimate coming in at $86.00 million and the highest estimate coming in at $86.44 million. Genomic Health reported sales of $81.97 million in the same quarter last year, which would suggest a positive year over year growth rate of 5%. The company is scheduled to issue its next quarterly earnings results on Tuesday, August 1st.
According to Zacks, analysts expect that Genomic Health will report full year sales of $86.09 million for the current financial year, with estimates ranging from $352.49 million to $358.37 million. For the next year, analysts forecast that the business will post sales of $393.45 million per share, with estimates ranging from $389.71 million to $400.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Genomic Health.
Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, May 9th. The medical research company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $84 million for the quarter, compared to the consensus estimate of $86.21 million. Genomic Health had a negative return on equity of 6.80% and a negative net margin of 2.53%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.19) EPS.
A number of equities analysts have recently commented on GHDX shares. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 18th. Jefferies Group LLC increased their price target on shares of Genomic Health from $29.00 to $33.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Finally, Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a report on Wednesday, May 3rd. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $32.00.
In related news, insider Steven Shak sold 5,000 shares of the stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $33.27, for a total transaction of $166,350.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $30.68, for a total transaction of $253,110.00. Following the transaction, the director now directly owns 74,145 shares in the company, valued at approximately $2,274,768.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,468 shares of company stock worth $2,154,495. 46.20% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Dubuque Bank & Trust Co. acquired a new position in Genomic Health during the first quarter valued at approximately $142,000. Russell Investments Group Ltd. acquired a new position in Genomic Health during the fourth quarter valued at approximately $575,000. Norges Bank acquired a new position in Genomic Health during the fourth quarter valued at approximately $4,546,000. Teachers Advisors LLC raised its position in Genomic Health by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock valued at $935,000 after buying an additional 1,838 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Genomic Health by 28.7% in the first quarter. Nordea Investment Management AB now owns 53,607 shares of the medical research company’s stock valued at $1,688,000 after buying an additional 11,970 shares in the last quarter. 89.49% of the stock is currently owned by institutional investors.
Shares of Genomic Health (NASDAQ:GHDX) opened at 32.82 on Friday. The company’s market cap is $1.13 billion. Genomic Health has a 1-year low of $25.56 and a 1-year high of $33.97. The firm’s 50 day moving average is $31.56 and its 200-day moving average is $30.60.
ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/16/zacks-brokerages-anticipate-genomic-health-inc-ghdx-will-post-quarterly-sales-of-86-09-million.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.